Because NRP2 expression is significantly associated with poor prognosis in renal cell carcinomas, colorectal carcinomas, gastric carcinomas, osteosarcoma, breast, pancreatic, and bladder cancer (7–13), it has become an attractive target for cancer therapy. This evidence concerns the gene NRP2 and urinary bladder carcinoma.